Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Increased by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 37.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,755 shares of the biopharmaceutical company's stock after purchasing an additional 3,232 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Alnylam Pharmaceuticals were worth $2,766,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ALNY. Capital Research Global Investors increased its holdings in shares of Alnylam Pharmaceuticals by 32.9% in the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after purchasing an additional 1,724,610 shares during the period. Capital World Investors increased its holdings in Alnylam Pharmaceuticals by 0.6% in the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock worth $3,906,284,000 after buying an additional 92,101 shares during the period. Dimensional Fund Advisors LP raised its position in Alnylam Pharmaceuticals by 10.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 333,661 shares of the biopharmaceutical company's stock worth $78,520,000 after buying an additional 32,272 shares during the last quarter. First Trust Advisors LP lifted its stake in Alnylam Pharmaceuticals by 14.8% during the 4th quarter. First Trust Advisors LP now owns 327,782 shares of the biopharmaceutical company's stock valued at $77,130,000 after acquiring an additional 42,211 shares during the period. Finally, Alpha DNA Investment Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $710,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Up 3.7 %

Shares of NASDAQ ALNY traded up $8.95 during midday trading on Friday, reaching $251.56. 835,322 shares of the stock were exchanged, compared to its average volume of 876,121. The stock has a 50 day moving average price of $247.34 and a 200-day moving average price of $256.23. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The company has a market capitalization of $32.72 billion, a P/E ratio of -115.93 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now owns 81,526 shares of the company's stock, valued at $20,802,989.42. The trade was a 1.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CMO Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total value of $389,585.16. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,017,271.63. This represents a 11.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 59,984 shares of company stock worth $16,864,347 over the last quarter. 1.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ALNY shares. Wells Fargo & Company upped their target price on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a research note on Friday, March 21st. William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $280.00 to $328.00 in a research note on Monday, March 24th. Morgan Stanley cut their price objective on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a report on Friday, April 11th. Finally, Sanford C. Bernstein lowered their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $315.58.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.